Literature DB >> 21963333

Analyses related to the development of DSM-5 criteria for substance use related disorders: 2. Proposed DSM-5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients.

Deborah S Hasin1, Miriam C Fenton, Cheryl Beseler, Jung Yeon Park, Melanie M Wall.   

Abstract

BACKGROUND: A number of changes have been proposed and investigated in the criteria for substance use disorders in DSM-5. However, although clinical utility of DSM-5 is a high priority, relatively little of the empirical evidence supporting the changes was obtained from samples of substance abuse patients.
METHODS: Proposed changes were examined in 663 patients in treatment for substance use disorders, evaluated by experienced clinicians using the Psychiatric Research Interview for Substance and Mental Disorders (PRISM). Factor and item response theory analysis was used to investigate the dimensionality and psychometric properties of alcohol, cannabis, cocaine and heroin abuse and dependence criteria, and craving.
RESULTS: The seven dependence criteria, three of the abuse criteria (hazardous use; social/interpersonal problems related to use; neglect of roles to use), and craving form a unidimensional latent trait for alcohol, cannabis, cocaine and heroin. Craving did not add significantly to the total information offered by the dependence criteria, but adding the three abuse criteria and craving together did significantly increase total information for the criteria sets associated with alcohol, cannabis and heroin.
CONCLUSION: Among adult patients in treatment for substance disorders, the alcohol, cannabis, cocaine and heroin criteria for dependence, abuse (with the exception of legal problems), and craving measure a single underlying dimension. Results support the proposal to combine abuse and dependence into a single diagnosis in the DSM-5, omitting legal problems. Mixed support was provided for the addition of craving as a new criterion, warranting future studies of this important construct in substance use disorders.
Copyright © 2011. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21963333      PMCID: PMC3755770          DOI: 10.1016/j.drugalcdep.2011.09.005

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  67 in total

1.  An item-response theory analysis of DSM-IV alcohol-use disorder criteria and "binge" drinking in undergraduates.

Authors:  Cheryl L Beseler; Laura A Taylor; Robert F Leeman
Journal:  J Stud Alcohol Drugs       Date:  2010-05       Impact factor: 2.582

2.  The validity of DSM-IV cannabis abuse and dependence criteria in adolescents and the value of additional cannabis use indicators.

Authors:  Daniela Piontek; Ludwig Kraus; Stéphane Legleye; Gerhard Bühringer
Journal:  Addiction       Date:  2011-03-07       Impact factor: 6.526

3.  A Rasch model analysis of DSM-IV Alcohol abuse and dependence items in the National Epidemiological Survey on Alcohol and Related Conditions.

Authors:  Christopher W Kahler; David R Strong
Journal:  Alcohol Clin Exp Res       Date:  2006-07       Impact factor: 3.455

Review 4.  Item response theory and clinical measurement.

Authors:  Steven P Reise; Niels G Waller
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

5.  Commentary on Shand et al. (2011): Opioid use disorder as a condition of graded severity, similar to other substance use disorders.

Authors:  Deborah S Hasin
Journal:  Addiction       Date:  2011-03       Impact factor: 6.526

Review 6.  Substance use disorders: Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10).

Authors:  Deborah Hasin; Mark L Hatzenbuehler; Katherine Keyes; Elizabeth Ogburn
Journal:  Addiction       Date:  2006-09       Impact factor: 6.526

7.  Dimensionality of lifetime alcohol abuse, dependence and binge drinking.

Authors:  Deborah S Hasin; Cheryl L Beseler
Journal:  Drug Alcohol Depend       Date:  2008-12-17       Impact factor: 4.492

8.  Coherence of the dependence syndrome in cocaine users.

Authors:  K J Bryant; B J Rounsaville; T F Babor
Journal:  Br J Addict       Date:  1991-10

9.  Construct validity of the dependence syndrome as measured by DSM-IV for different psychoactive substances.

Authors:  A Feingold; B Rounsaville
Journal:  Addiction       Date:  1995-12       Impact factor: 6.526

10.  Factor and item-response analysis DSM-IV criteria for abuse of and dependence on cannabis, cocaine, hallucinogens, sedatives, stimulants and opioids.

Authors:  Nathan A Gillespie; Michael C Neale; Carol A Prescott; Steven H Aggen; Kenneth S Kendler
Journal:  Addiction       Date:  2007-06       Impact factor: 6.526

View more
  50 in total

1.  Co-occurrence of alcohol, drug use, DSM-5 alcohol use disorder, and symptoms of drug use disorder on both sides of the U.S.-Mexico border.

Authors:  Guilherme Borges; Sarah Zemore; Ricardo Orozco; Cheryl J Cherpitel; Yu Ye; Jason Bond; Jane Carlisle Maxwell; Lynn Wallisch
Journal:  Alcohol Clin Exp Res       Date:  2015-04       Impact factor: 3.455

2.  Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population.

Authors:  Deborah S Hasin; Dvora Shmulewitz; Malka Stohl; Eliana Greenstein; Christina Aivadyan; Kara Morita; Tulshi Saha; Efrat Aharonovich; Jeesun Jung; Haitao Zhang; Edward V Nunes; Bridget F Grant
Journal:  Drug Alcohol Depend       Date:  2015-04-06       Impact factor: 4.492

3.  Item response theory analyses of DSM-IV and DSM-5 stimulant use disorder criteria in an American Indian community sample.

Authors:  David A Gilder; Ian R Gizer; Philip Lau; Cindy L Ehlers
Journal:  Drug Alcohol Depend       Date:  2013-10-23       Impact factor: 4.492

4.  Inter-observer reliability of DSM-5 substance use disorders.

Authors:  Cécile M Denis; Joel Gelernter; Amy B Hart; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

5.  Childhood maltreatment, 9/11 exposure, and latent dimensions of psychopathology: A test of stress sensitization.

Authors:  Jacquelyn L Meyers; Sarah R Lowe; Nicholas R Eaton; Robert Krueger; Bridget F Grant; Deborah Hasin
Journal:  J Psychiatr Res       Date:  2015-05-16       Impact factor: 4.791

6.  Nosologic Comparisons of DSM-IV and DSM-5 Alcohol and Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Risë B Goldstein; S Patricia Chou; Sharon M Smith; Jeesun Jung; Haitao Zhang; Tulshi D Saha; Roger P Pickering; W June Ruan; Boji Huang; Bridget F Grant
Journal:  J Stud Alcohol Drugs       Date:  2015-05       Impact factor: 2.582

7.  Parental alcohol history differentially predicts offspring disorders in distinct subgroups in Israel.

Authors:  Jacquelyn L Meyers; Dvora Shmulewitz; Jennifer C Elliott; Ronald G Thompson; Efrat Aharonovich; Baruch Spivak; Abraham Weizman; Amos Frisch; Bridget F Grant; Deborah S Hasin
Journal:  J Stud Alcohol Drugs       Date:  2014-09       Impact factor: 2.582

8.  Drug use on both sides of the US-Mexico border.

Authors:  Guilherme Borges; Sarah E Zemore; Ricardo Orozco; Cheryl J Cherpitel; Priscilla Martínez; Lynn Wallisch
Journal:  Salud Publica Mex       Date:  2018 Jul-Aug

9.  Comparing factor, class, and mixture models of cannabis initiation and DSM cannabis use disorder criteria, including craving, in the Brisbane longitudinal twin study.

Authors:  Thomas S Kubarych; Kenneth S Kendler; Steven H Aggen; Ryne Estabrook; Alexis C Edwards; Shaunna L Clark; Nicholas G Martin; Ian B Hickie; Michael C Neale; Nathan A Gillespie
Journal:  Twin Res Hum Genet       Date:  2014-03-03       Impact factor: 1.587

10.  Validity of proposed DSM-5 diagnostic criteria for nicotine use disorder: results from 734 Israeli lifetime smokers.

Authors:  D Shmulewitz; M M Wall; E Aharonovich; B Spivak; A Weizman; A Frisch; B F Grant; D Hasin
Journal:  Psychol Med       Date:  2013-01-14       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.